ES2967379T3 - Combinación de ácido para-aminohippúrico (PAH) y complejos radio-etiquetados para el tratamiento del cáncer - Google Patents

Combinación de ácido para-aminohippúrico (PAH) y complejos radio-etiquetados para el tratamiento del cáncer Download PDF

Info

Publication number
ES2967379T3
ES2967379T3 ES21810930T ES21810930T ES2967379T3 ES 2967379 T3 ES2967379 T3 ES 2967379T3 ES 21810930 T ES21810930 T ES 21810930T ES 21810930 T ES21810930 T ES 21810930T ES 2967379 T3 ES2967379 T3 ES 2967379T3
Authority
ES
Spain
Prior art keywords
pah
salt
cancer
combination
radiolabeled complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21810930T
Other languages
English (en)
Spanish (es)
Inventor
Marian Meckel
Theresa Osl
Konstantin Zhernosekov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ITM Isotope Technologies Munich SE
Original Assignee
ITM Isotope Technologies Munich SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ITM Isotope Technologies Munich SE filed Critical ITM Isotope Technologies Munich SE
Application granted granted Critical
Publication of ES2967379T3 publication Critical patent/ES2967379T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES21810930T 2020-11-05 2021-11-05 Combinación de ácido para-aminohippúrico (PAH) y complejos radio-etiquetados para el tratamiento del cáncer Active ES2967379T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2020/081143 WO2022096103A1 (en) 2020-11-05 2020-11-05 Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
PCT/EP2021/080822 WO2022096673A1 (en) 2020-11-05 2021-11-05 Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer

Publications (1)

Publication Number Publication Date
ES2967379T3 true ES2967379T3 (es) 2024-04-30

Family

ID=73138835

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21810930T Active ES2967379T3 (es) 2020-11-05 2021-11-05 Combinación de ácido para-aminohippúrico (PAH) y complejos radio-etiquetados para el tratamiento del cáncer

Country Status (13)

Country Link
US (1) US20230414796A1 (cg-RX-API-DMAC7.html)
EP (1) EP4065176B1 (cg-RX-API-DMAC7.html)
JP (1) JP7531707B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230127212A (cg-RX-API-DMAC7.html)
CN (1) CN116981487A (cg-RX-API-DMAC7.html)
AU (1) AU2021375728A1 (cg-RX-API-DMAC7.html)
DK (1) DK4065176T3 (cg-RX-API-DMAC7.html)
ES (1) ES2967379T3 (cg-RX-API-DMAC7.html)
FI (1) FI4065176T3 (cg-RX-API-DMAC7.html)
HU (1) HUE065304T2 (cg-RX-API-DMAC7.html)
PL (1) PL4065176T3 (cg-RX-API-DMAC7.html)
WO (2) WO2022096103A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202304769B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR2022007815A1 (tr) * 2022-05-13 2023-11-21 Ege Ueniversitesi Idari Ve Mali Islerdaire Bsk Yüksek stabi̇li̇teye ve radyoi̇şaretleme veri̇mi̇ne sahi̇p radyofarmasöti̇kler ve bahsedi̇len radyofarmasöti̇kleri̇ i̇çeren teranosti̇k ki̇t
CN115212322B (zh) * 2022-06-01 2024-01-16 原子高科股份有限公司 一种用于放射性药物制备的冻干药盒及其制备方法
WO2025113628A1 (en) * 2023-11-30 2025-06-05 Full-Life Technologies Hk Limited Sstr receptor targeting radio compounds and uses thereof
EP4763231A1 (en) * 2024-12-20 2026-06-24 ITM Isotope Technologies Munich SE Para-aminohippuric acid as a stabilizer in radiopharmaceutical compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006176427A (ja) 2004-12-21 2006-07-06 Geno Membrane:Kk エストロン3硫酸トランスポーター活性の阻害剤
US20070025910A1 (en) 2005-07-29 2007-02-01 Norenberg Jeffrey P Anticancer therapy
US20070166774A1 (en) * 2006-01-17 2007-07-19 Groman Ernest V Functional immunoassay
CA2686933A1 (en) * 2007-04-06 2008-10-16 The Johns Hopkins University Methods and compositions for the treatment of cancer
JP5843338B2 (ja) 2011-08-05 2016-01-13 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 放射標識された前立腺特異的膜抗原阻害剤
SMT202300035T1 (it) 2013-03-15 2023-05-12 Cancer Targeted Tech Llc Metodi per preparare agenti di pet imaging marcati con 18f indirizzati al psma e metodi diagnostici con gli stessi
EP2862857A1 (en) 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
AU2014336638C1 (en) 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CA3060143A1 (en) 2017-05-24 2018-11-29 Itm Isotopen Technologien Munchen Ag Novel psma-binding agents and uses thereof
WO2020108753A1 (en) 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
WO2020224780A1 (en) * 2019-05-08 2020-11-12 ITM Isotopen Technologien München AG Para-aminohippuric acid (pah) as a renal protective substance

Also Published As

Publication number Publication date
WO2022096103A1 (en) 2022-05-12
DK4065176T3 (da) 2024-01-02
FI4065176T3 (fi) 2024-01-18
ZA202304769B (en) 2024-10-30
PL4065176T3 (pl) 2024-03-18
AU2021375728A9 (en) 2024-06-20
CN116981487A (zh) 2023-10-31
JP7531707B2 (ja) 2024-08-09
US20230414796A1 (en) 2023-12-28
CA3171718A1 (en) 2022-05-12
AU2021375728A1 (en) 2023-06-15
HUE065304T2 (hu) 2024-05-28
EP4065176A1 (en) 2022-10-05
KR20230127212A (ko) 2023-08-31
EP4065176B1 (en) 2023-10-11
JP2023547689A (ja) 2023-11-13
WO2022096673A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
ES3011272T3 (en) Dual mode radiotracer and -therapeutics
ES2938721T3 (es) Acido para-aminohipúrico (PAH) como sustancia protectora renal
JP7531707B2 (ja) 癌を処置するためのパラアミノ馬尿酸(pah)および放射能標識された複合体の組合せ
US12605447B2 (en) Stable formulations for radionuclide complexes
CA3117763A1 (en) Novel tumor antigen binding agents and uses thereof
CA3171718C (en) Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
RU2842991C1 (ru) Комбинация пара-аминогиппуровой кислоты (паг) и меченных радиоактивным изотопом комплексов, предназначенная для лечения рака
HK40078095B (en) Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
HK40078095A (en) Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
RU2804349C2 (ru) Парааминогиппуровая кислота (паг) как вещество для защиты почек
HK40065088B (en) Para-aminohippuric acid (pah) as a renal protective substance
HK40065088A (en) Para-aminohippuric acid (pah) as a renal protective substance
WO2025218931A1 (en) Stable formulations comprising 225-actinium labeled complexes and methods for preparing the same